Trial reportAIDS research and human retroviruses2013
Partner characteristics predicting HIV-1 set point in sexually acquired HIV-1 among African seroconverters.
Trial report in AIDS research and human retroviruses, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 22 citations in OpenAlex.
- Circumcision status at HIV infection is not associated with plasma viral load in men: analysis of specimens from a randomized controlled trial.BMC infectious diseases · 2018Trial
- Association between male circumcision and incidence of syphilis in men and women: a prospective study in HIV-1 serodiscordant heterosexual African couples.The Lancet. Global health · 2014Trial
- Upregulation of IFN-stimulated genes persists beyond the transitory broad immunologic changes of acute HIV-1 infection.iScience · 2023Article
- Upregulation of PTPRC and Interferon Response Pathways in HIV-1 Seroconverters Prior to Infection.The Journal of infectious diseases · 2023Article
- Why does age at HIV infection correlate with set point viral load? An evolutionary hypothesis.Epidemics · 2022Article
- Phylogenetic estimation of the viral fitness landscape of HIV-1 set-point viral load.Virus evolution · 2022Article
- Schistosomiasis was not associated with higher HIV-1 plasma or genital set point viral loads among HIV seroconverters from four cohort studies.PLoS neglected tropical diseases · 2019Article
- HIV risk associated with serum medroxyprogesterone acetate levels among women in East and southern Africa.AIDS (London, England) · 2019Article
- Article
- HLA Class I Downregulation by HIV-1 Variants from Subtype C Transmission Pairs.Journal of virology · 2018Article
- A Practical Guide to Estimating the Heritability of Pathogen Traits.Molecular biology and evolution · 2018Article
- Viral genetic variation accounts for a third of variability in HIV-1 set-point viral load in Europe.PLoS biology · 2017Article
- Replication Capacity of Viruses from Acute Infection Drives HIV-1 Disease Progression.Journal of virology · 2017Article
- Estimating the Respective Contributions of Human and Viral Genetic Variation to HIV Control.PLoS computational biology · 2017Article
- Host genetic and viral determinants of HIV-1 RNA set point among HIV-1 seroconverters from sub-saharan Africa.Journal of virology · 2015Article
- Virulence and pathogenesis of HIV-1 infection: an evolutionary perspective.Science (New York, N.Y.) · 2014Review
- Effects of Succinic Acid and Other Microbial Fermentation Products on HIV Expression in Macrophages.BioResearch open access · 2013Article
- The natural history of HIV infection.Current opinion in HIV and AIDS · 2013Review
- Plasma viral loads during early HIV-1 infection are similar in subtype C- and non-subtype C-infected African seroconverters.The Journal of infectious diseases · 2013Article
- Intrinsic Replication Competences of HIV Strains After Zidovudine/Lamivudine/Nevirapine Treatment in the Philippines.Journal of the International Association of Providers of AIDS CareArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
Abstract
Plasma HIV-1 RNA set point is an important predictor of HIV-1 disease progression. We hypothesized that inoculum size and HIV-1 exposure prior to HIV-1 transmission may modulate set point. We evaluated predictors of set point among 141 African HIV-1 seroconverters and their HIV-1-infected study partners. We compared characteristics of seroconverters and their HIV-1-infected partners and HIV-1 set point. Data were from a clinical trial of genital HSV-2 suppression with acyclovir to reduce HIV-1 transmission in HIV-1 serodiscordant couples with HIV-1 transmission linkage assigned through virus sequencing. Our analysis includes data from all transmissions including those with transmission linkage to the HIV-1-infected "source partner" and those that were not linked to their HIV-1-infected study partner. In multivariable analysis, higher plasma HIV-1 in source partners was associated with higher seroconverter set point ( + 0.44 log10 copies/ml per log(10) source partner plasma HIV-1, p < 0.001). In addition, bacterial vaginosis (BV) among female source partners near the time of infection was associated with higher set point in their male seroconverters ( + 0.49 log(10), p = 0.04). Source partner characteristics associated with lower set point included male circumcision ( - 0.63 log(10), p = 0.03) and assignment to acyclovir ( - 0.44 log10, p = 0.02). The proportion of variation in set point explained by plasma HIV-1 RNA of the source partner, after controlling for other factors, was 0.06. Source partner plasma HIV-1 level is the most significant predictor of seroconverter set point, possibly reflecting characteristics of the transmitted virus. Acyclovir use, BV among women source partners, and circumcision among male source partners may alter the set point by affecting transmitted virus inoculum in the source partners' genital compartment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.